Related Experiment Videos

Effect of Fenoterol on PAF-induced lung edema in isolated and perfused rabbit lungs

L Pesce1, S Tristano, E Friedman

  • 1Unidad de Fisiologia Respiratoria, Instituto de Medicina Experimental, Facultad de Medicina, Escuela Luis Razetti, Universidad Central de Venezuela, Caracas.

Respiration Physiology
|December 29, 1998
PubMed

Insights

Fenoterol effectively inhibited pulmonary hypertension and lung edema caused by platelet-activating factor (PAF). This study demonstrates fenoterol

Area of Science:

  • Pulmonary Circulation Research
  • Pharmacology
  • Respiratory Physiology

Background:

  • Platelet-activating factor (PAF) is implicated in pulmonary vasoconstriction and edema.
  • Understanding the mechanisms of PAF-induced pulmonary responses is crucial for developing effective treatments.

Purpose of the Study:

  • To investigate the effects of fenoterol on platelet-activating factor (PAF)-induced pulmonary hypertension and edema.
  • To determine if fenoterol can mitigate the adverse effects of PAF in isolated rabbit lungs.

Main Methods:

  • Utilized 28 isolated and perfused rabbit lungs.
  • Administered varying doses of PAF (low and high) to induce pulmonary responses.
  • Treated experimental groups with fenoterol prior to PAF administration to assess its inhibitory effects.

Main Results:

  • Fenoterol significantly prevented the elevation of pulmonary artery pressure (Ppa) induced by both low and high doses of PAF.
  • Fenoterol administration markedly reduced the fluid filtration rate (FFR) associated with PAF exposure.
  • PAF induced significant pulmonary vasoconstriction and increased lung edema, effects reversed by fenoterol.

Conclusions:

  • Platelet-activating factor (PAF) exerts a potent vasoconstrictor effect on the pulmonary circulation, leading to lung edema.
  • Fenoterol demonstrates significant efficacy in inhibiting PAF-induced pulmonary hypertension and edema in an isolated lung model.
  • These findings suggest fenoterol as a potential therapeutic agent for conditions involving PAF-mediated pulmonary dysfunction.

Related Concept Videos